

Extraordinary General Shareholders' Meeting

Faes Farma's Shareholders' Meeting approves the acquisition of 100% of SIFI

- **Shareholder support consolidates the transaction as a transformational step for the company's strategy**
- **The acquisition consolidates Faes Farma as a leading ophthalmology company with one of the most comprehensive offerings in the sector**
- **The integration strengthens the company's direct international presence in key markets such as Italy, Romania, France, and Turkey**

Bilbao, July 16, 2025. Faes Farma held an Extraordinary General Shareholders' Meeting today at which it approved the acquisition of 100% of the capital of SIFI SpA, after obtaining majority shareholder support. This approval represents a decisive step forward in the execution of Faes Farma's strategic plan for 2030, consolidating one of its four key levers: growth through M&A operations.

The acquisition represents a transformational step in Faes Farma's ambition and in the company's leadership in ophthalmology, a strategic area with high potential. SIFI brings a consolidated ophthalmic products business, as well as an emerging ophthalmic CMO business unit and a strategic opportunity with Ankantior, an innovative therapy product for an ultra-rare disease that is already approved in Europe (marketed in Germany in October 2024 and in Spain in August 2025).

In addition, SIFI strengthens Faes Farma's international presence in key markets such as Italy, Romania, France, and Turkey with a consolidated portfolio of more than 60 ophthalmic solutions and five other recent launches. This milestone, together with the recent acquisition of Laboratorio Edol, also specialising in ophthalmology, enables Faes Farma to offer one of the most comprehensive offerings in the sector in this therapeutic area and to develop business opportunities through the attraction and expansion of in-licensing and out-licensing.

The transaction also provides access to highly specialized industrial and R&D capabilities, which will accelerate innovation and create a scalable platform for future growth. In addition, the integration of products will generate cross-selling opportunities, improving growth and margins through operational and cost efficiencies.

As previously announced, the transaction values the company at €270 million, ensuring a pro forma net debt/EBITDA ratio of less than 2x. From a financial standpoint, the transaction has an immediate impact on results, with expected sustainable growth in the short term and no impact on the company's dividend policy, maintaining its commitment to a 50% payout.

The company will continue to work on the remaining phases of the process until its final completion, subject to the usual regulatory conditions.



About Faes Farma

We are a company with more than 90 years of experience and a presence in more than 130 countries through marketed or licensed products. We combine passion, science, and innovation to transform people's health. We research, produce, and market prescription medicines, healthcare products, and animal nutrition products, and we aspire to become a leading pharmaceutical group in excellence and innovation. At Faes Farma, we are guided by our values to offer the highest quality solutions in health and well-being, with the patient as our priority; to develop innovative products that adapt to the needs of society and to guarantee integrity, transparency, and commitment through responsible management and excellence.

Press contact

María Marín
Investor Relations and External Communications Director
mmarin@faes.es
Faes Farma

Cristina López Reques
| +34 663 371 770 | clopez@harmon.es
Harmon Corporate Affairs